Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial update for ixekizumab in Japanese participants with generalized pustular psoriasis and erythrodermic psoriasis; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Generalized Pustular Psoriasis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2021-08-13